BioCentury
ARTICLE | Clinical News

Opdivo nivolumab regulatory update

April 25, 2016 7:00 AM UTC

FDA accepted and granted Priority Review to an sBLA from Bristol-Myers Squibb for Opdivo nivolumab to treat classical Hodgkin’s lymphoma after prior therapies. The PDUFA date is Sept. 1. Opdivo has br...